Press Release: ELBIT IMAGING ANNOUNCES THAT GAMIDA CELL SUBMITTED CONFIDENTIAL FILINGS AS PART OF PURSUING VARIOUS ALTERNATIVES FOR RAISING CAPITAL
ELBIT IMAGING ANNOUNCES THAT GAMIDA CELL SUBMITTED CONFIDENTIAL FILINGS AS PART OF PURSUING VARIOUS ALTERNATIVES FOR RAISING CAPITAL
Tel Aviv, Israel, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Elbit Imaging Ltd. (TASE, NASDAQ: EMITF) ("Elbit" or the "Company") announced today that Gamida Cell Ltd. ("Gamida"), in which the Company indirectly holds approximately 16% of its issued and paid up share capital (approx. 8% on a fully diluted basis), is pursuing various alternatives for raising additional capital, including an Initial Public Offering of its ordinary shares in the Unites States, for which it has confidentially submitted draft filings of a registration statement to the U.S. Securities and Exchange Commission..
As of this date, there is no certainty that such additional financing will be consummated, or what will be the terms of such financing, since, inter alia, such financing is subject to the satisfaction of various conditions, including the existence of appropriate market conditions, obtaining required approvals, the realization of risk factors related to Gamida, developments in its business or in the financial markets and the markets in which it operates, etc.
This report shall not constitute an offer to sell and/or the solicitation of an offer to buy any securities.
The Company holds approximately 89% of the share capital of Elbit Medical Technologies Ltd. (TASE: EMTC-M) (approximately 58% on a fully diluted basis) which, in turn, holds approximately 18% of the share capital in Gamida (approximately 13% on a fully diluted basis).
About Elbit Imaging Ltd.
Elbit Imaging Ltd. operates in the following principal fields of business: (i) medical industries through our indirect holdings in Insightec Ltd. and Gamida Cell Ltd.; (ii) land in India which is designated for sale (and which was initially designated for residential projects); and (iii) land in Eastern Europe which is designated for sale (and which was initially designated for development of commercial centers).
For Further Information:
Company Contact
Ron Hadassi
CEO and Chairman of the Board of Directors
Tel: +972-3-608-6048
Fax: +972-3-608-6050
ron@elbitimaging.com
------------------------------------------
(END) Dow Jones Newswires
August 31, 2018 06:15 ET (10:15 GMT)
*DJ Elbit Imaging Says Gamida Cell Pursuing Various Alternatives for Raising Additional Cap, Including an IPO of Ordinary Shrs in U.S. >EMITF
(MORE TO FOLLOW) Dow Jones Newswires (212-416-2800)
August 31, 2018 06:16 ET (10:16 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
新闻稿：Elbit Imaging宣布Gamida cell提交了机密文件，作为寻求各种融资替代方案的一部分
Elbit Imaging宣布Gamida cell提交了机密文件，作为寻求各种融资替代方案的一部分
以色列特拉维夫，2018年8月31日(环球通讯社)-Elbit成像有限公司(TASE，NASDAQ：EMITF)(“ELBIT”或“公司”)今天宣布Gamida Cell Ltd。(“Gamida”)，其中本公司间接持有其已发行及缴足股本约16%(约8%(在完全稀释的基础上)，正在寻求筹集额外资本的各种替代方案，包括其在美国的普通股首次公开发行(IPO)，为此，该公司已向美国证券交易委员会(SEC)秘密提交了一份注册声明的文件草案。
截至目前，尚不能确定此类额外融资是否会得到完善，也不确定此类融资的条款如何，因为，除其他外，此类融资须满足各种条件，包括存在适当的市场条件、获得所需的批准、与Gamida相关的风险因素的实现、其业务或金融市场的发展以及其运营的市场等。
本报告不应构成出售要约和/或购买任何证券的要约招揽。
该公司持有埃尔比特医疗技术有限公司约89%的股本。(TASE：EMTC-M)(完全稀释的基础上约58%)，而后者又持有Gamida约18%的股本(完全稀释的基础上约13%)。
关于Elbit成像有限公司
Elbit Imaging Ltd.在以下主要业务领域开展业务：(I)通过我们在InSightec Ltd.和Gamida Cell Ltd.的间接持股的医疗行业；(Ii)印度指定出售的土地(最初指定用于住宅项目)；以及(Iii)东欧指定出售的土地(最初指定用于发展商业中心)。
欲获知更多信息，请访问：
公司联系
罗恩·哈达西
首席执行官兼董事会主席
Tel: +972-3-608-6048
Fax: +972-3-608-6050
Ron@elbitimaging.com
------------------------------------------
(结束)道琼斯通讯社
August 31, 2018 06:15 ET (10:15 GMT)
*DJ Elbit Imaging表示Gamida Cell寻求各种替代方案来筹集额外的上限，包括美国普通SHR的IPO>EMITF
(后续更多)道琼斯通讯社(212-416-2800)
August 31, 2018 06:16 ET (10:16 GMT)
版权所有(C)2018 Dow Jones&Company，Inc.
